These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 20101016)
1. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data". Luepker RV Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016 [No Abstract] [Full Text] [Related]
2. Bringing the FDA's Information to Market. Woloshin S; Schwartz LM Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960 [No Abstract] [Full Text] [Related]
3. Vioxx's history and the need for better procedures and better testing. Gilhooley M Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218 [No Abstract] [Full Text] [Related]
4. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Ross JS; Madigan D; Hill KP; Egilman DS; Wang Y; Krumholz HM Arch Intern Med; 2009 Nov; 169(21):1976-85. PubMed ID: 19933959 [TBL] [Abstract][Full Text] [Related]
5. Withdrawal of rofecoxib - a wake up call for drug safety. Mishra P; Palaian S Kathmandu Univ Med J (KUMJ); 2004; 2(4):360. PubMed ID: 16388250 [No Abstract] [Full Text] [Related]
6. COX-2 inhibitors and the heart: putting risk in perspective. Bobadilla RV; Barnett EM; Randels CL Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003 [No Abstract] [Full Text] [Related]
7. A retrospective analysis of VIOXX in Australia: using clinical trial data and linked administrative health data to predict patient groups at risk of an adverse drug event. Whitstock MT; Pearce CM; Ridout SC; Eckermann EJ Aust N Z J Public Health; 2010 Aug; 34(4):431-2. PubMed ID: 20649787 [No Abstract] [Full Text] [Related]
8. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. Psaty BM; Kronmal RA JAMA; 2008 Apr; 299(15):1813-7. PubMed ID: 18413875 [TBL] [Abstract][Full Text] [Related]
9. Drug safety on trial. Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579 [No Abstract] [Full Text] [Related]
10. Drug safety special: the safety catch. Wadman M Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591 [No Abstract] [Full Text] [Related]
11. Failing the public health--rofecoxib, Merck, and the FDA. Topol EJ N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193 [No Abstract] [Full Text] [Related]
12. Don't blame it all on the bogey. Day M BMJ; 2007 Jun; 334(7606):1250-1. PubMed ID: 17569929 [TBL] [Abstract][Full Text] [Related]
13. Drug safety special: chasing shadows. Frantz S Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592 [No Abstract] [Full Text] [Related]
14. The withdrawal of rofecoxib. Arellano FM Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267 [No Abstract] [Full Text] [Related]
15. Learning the value of drugs--is rofecoxib a regulatory success story? Eisenberg RS N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222 [No Abstract] [Full Text] [Related]
16. Lessons learned after the withdrawal of rofecoxib. Giaquinta D Manag Care Interface; 2004 Nov; 17(11):25-6, 46. PubMed ID: 15573801 [No Abstract] [Full Text] [Related]
17. Rofecoxib, Merck, and the FDA. Kim PS; Reicin AS N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342 [No Abstract] [Full Text] [Related]
18. Experts point to lessons learned from controversy over rofecoxib safety. Hampton T JAMA; 2005 Jan; 293(4):413-4. PubMed ID: 15671414 [No Abstract] [Full Text] [Related]
19. Adverse cardiovascular effects of rofecoxib. Furberg CD N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442 [No Abstract] [Full Text] [Related]